IBI-129
- Generic Name
- IBI-129
Hansoh Pharma's HS-20093 ADC Granted Breakthrough Therapy Designation for SCLC in China
• Jiangsu Hansoh's HS-20093, a B7-H3-targeted ADC, has received Breakthrough Therapy Designation from China's NMPA for extensive-stage small cell lung cancer (ES-SCLC) following first-line treatment.
• HS-20093 is the first B7-H3-targeted ADC to enter Phase III development in China for second-line SCLC treatment, potentially setting a new standard of care.
• The prevalence of SCLC in China is expected to rise significantly, underscoring the urgent need for innovative treatments like HS-20093 to improve patient outcomes.
• Jiangsu Hansoh is developing two additional ADCs, HS-20089 and HS-20105, for various solid tumors, reinforcing its oncology market position in China.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath